Lynn Anne Bristol

Array ( [id] => 10233250 [patent_doc_number] => 20150118244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'ANTI-TUMOR ANTIBODIES AS PREDICTIVE OR PROGNOSTIC BIOMARKERS OF EFFICACY AND SURVIVAL IN IPILIMUMAB-TREATED PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/399554 [patent_app_country] => US [patent_app_date] => 2013-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 20117 [patent_no_of_claims] => 129 [patent_no_of_ind_claims] => 113 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240454 [patent_doc_number] => 20150125449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'Single-Arm Monovalent Antibody Constructs and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/399789 [patent_app_country] => US [patent_app_date] => 2013-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 41569 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 61 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11794160 [patent_doc_number] => 09403912 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-02 [patent_title] => 'Anti-ErbB2 antibody variants' [patent_app_type] => utility [patent_app_number] => 14/399265 [patent_app_country] => US [patent_app_date] => 2013-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 11334 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10201549 [patent_doc_number] => 20150086538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'ANTIBODY LIGHT CHAINS' [patent_app_type] => utility [patent_app_number] => 14/391853 [patent_app_country] => US [patent_app_date] => 2013-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10161 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14391853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134382 [patent_doc_number] => 20130295096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'DEGRADED AGONIST ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/856119 [patent_app_country] => US [patent_app_date] => 2013-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 31230 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13856119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635685 [patent_doc_number] => 09353179 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Binding molecules' [patent_app_type] => utility [patent_app_number] => 13/837402 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 22043 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13837402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10225786 [patent_doc_number] => 20150110779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'METHODS FOR PREDICTING GASTROINTESTINAL IMMUNE-RELATED ADVERSE EVENTS (GI-IRAE) IN PATIENTS TREATED WITH MODULATION OF THE CO-STIMULATORY PATHWAY' [patent_app_type] => utility [patent_app_number] => 14/383589 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 36150 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14383589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628732 [patent_doc_number] => 09346877 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Binding molecules' [patent_app_type] => utility [patent_app_number] => 13/837520 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 22039 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13837520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11575764 [patent_doc_number] => 09631011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-25 [patent_title] => 'Gremlin-1 antibody' [patent_app_type] => utility [patent_app_number] => 14/385483 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 11521 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 245 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14385483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12509346 [patent_doc_number] => 10000567 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => Humanized antibodies to cluster of differentiation 3 (CD3) [patent_app_type] => utility [patent_app_number] => 14/408128 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 19557 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14408128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166140 [patent_doc_number] => 09884902 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'CTLA-4 variants' [patent_app_type] => utility [patent_app_number] => 14/399685 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 24230 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663655 [patent_doc_number] => 20160009799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'PHARMACEUTICAL COMPOSITION FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/382745 [patent_app_country] => US [patent_app_date] => 2013-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 14061 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14382745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8928424 [patent_doc_number] => 20130184185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-18 [patent_title] => 'METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN' [patent_app_type] => utility [patent_app_number] => 13/784382 [patent_app_country] => US [patent_app_date] => 2013-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 14973 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13784382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9805223 [patent_doc_number] => 20150017169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-15 [patent_title] => 'Sequence Asymmetric Modified IgG4 Bispecific Antibodies' [patent_app_type] => utility [patent_app_number] => 14/380310 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 22352 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 26 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9806587 [patent_doc_number] => 20150018531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-15 [patent_title] => 'ANTI SEZ6 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/380665 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 60 [patent_no_of_words] => 71869 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9806584 [patent_doc_number] => 20150018529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-15 [patent_title] => 'Sequence Symmetric Modified IgG4 Bispecific Antibodies' [patent_app_type] => utility [patent_app_number] => 14/380309 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 24582 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173911 [patent_doc_number] => 20130315896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44' [patent_app_type] => utility [patent_app_number] => 13/764724 [patent_app_country] => US [patent_app_date] => 2013-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 23404 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13764724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240448 [patent_doc_number] => 20150125443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES' [patent_app_type] => utility [patent_app_number] => 14/374612 [patent_app_country] => US [patent_app_date] => 2013-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16241 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14374612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15816571 [patent_doc_number] => 10633451 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine [patent_app_type] => utility [patent_app_number] => 14/376364 [patent_app_country] => US [patent_app_date] => 2013-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 24 [patent_no_of_words] => 32228 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14376364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10574164 [patent_doc_number] => 09296791 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-29 [patent_title] => 'Mutant protein' [patent_app_type] => utility [patent_app_number] => 13/740793 [patent_app_country] => US [patent_app_date] => 2013-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 23 [patent_no_of_words] => 14457 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13740793 [rel_patent_id] =>[rel_patent_doc_number] =>)